57.30 +2.64 (4.83%)
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
57.3
Today’s High
57.3
52 Week Low
11.14
52 Week High
54.66
Key Metrics
- Market Cap (In Cr) 41.11
- Beta -0.19
- Div. Yield (%) 0
- P/B 2.51
- TTM P/E 28.8
- Peg Ratio 0.07
- Sector P/E 28.39
- D/E 0.1
- Open Price 57.3
- Prev Close 54.66
Analysis
Price Analysis
-
1 Week27.57%
-
3 Months37.92%
-
6 Month46.54%
-
YTD98.71%
-
1 Year275.14%
Risk Meter
- 55% Low risk
- 55% Moderate risk
- 55% Balanced Risk
- 55% High risk
- 55% Extreme risk
Recos
0 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Shukra Pharmaceuticals News
Given multibagger return YTD, this pharma stock fixes record date for dividend
2 min read . 10 Sep 2022Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 20.49
- Selling/ General/ Admin Expenses Total
- 4.9
- Depreciation/ Amortization
- 1.66
- Other Operating Expenses Total
- 2.35
- Total Operating Expense
- 19.26
- Operating Income
- 1.22
- Net Income Before Taxes
- 1.02
- Net Income
- 0.75
- Diluted Normalized EPS
- 4.79
- Period
- 2022
- Total Assets
- 35.11
- Total Liabilities
- 18.76
- Total Equity
- 16.35
- Tangible Book Valueper Share Common Eq
- 104.43
- Period
- 2022
- Cashfrom Operating Activities
- 7.78
- Cashfrom Investing Activities
- -1.53
- Cashfrom Financing Activities
- -6.68
- Net Changein Cash
- -0.42
- Period
- 2021
- Total Revenue
- 11.2
- Selling/ General/ Admin Expenses Total
- 4.07
- Depreciation/ Amortization
- 1.47
- Other Operating Expenses Total
- 2.92
- Total Operating Expense
- 11.42
- Operating Income
- -0.23
- Net Income Before Taxes
- 0.1
- Net Income
- 0.19
- Diluted Normalized EPS
- 2.01
- Period
- 2021
- Total Assets
- 35.61
- Total Liabilities
- 20.01
- Total Equity
- 15.6
- Tangible Book Valueper Share Common Eq
- 99.63
- Period
- 2021
- Cashfrom Operating Activities
- 0.54
- Cashfrom Investing Activities
- -1.89
- Cashfrom Financing Activities
- 1.74
- Net Changein Cash
- 0.38
- Period
- 2020
- Total Revenue
- 11.85
- Selling/ General/ Admin Expenses Total
- 4.4
- Depreciation/ Amortization
- 1.48
- Other Operating Expenses Total
- 2.9
- Total Operating Expense
- 11.79
- Operating Income
- 0.06
- Net Income Before Taxes
- 0.17
- Net Income
- 0.04
- Diluted Normalized EPS
- -0.19
- Period
- 2020
- Total Assets
- 33.55
- Total Liabilities
- 18.13
- Total Equity
- 15.41
- Tangible Book Valueper Share Common Eq
- 98.43
- Period
- 2020
- Cashfrom Operating Activities
- 1.24
- Cashfrom Investing Activities
- -3.11
- Cashfrom Financing Activities
- 1.99
- Net Changein Cash
- 0.12
- Period
- 2019
- Total Revenue
- 5.66
- Selling/ General/ Admin Expenses Total
- 1.96
- Depreciation/ Amortization
- 0.96
- Other Operating Expenses Total
- 1.06
- Total Operating Expense
- 4.97
- Operating Income
- 0.69
- Net Income Before Taxes
- 0.72
- Net Income
- 0.46
- Diluted Normalized EPS
- 2.95
- Period
- 2019
- Total Assets
- 28.39
- Total Liabilities
- 13.01
- Total Equity
- 15.38
- Tangible Book Valueper Share Common Eq
- 98.2
- Period
- 2019
- Cashfrom Operating Activities
- 0.26
- Cashfrom Investing Activities
- -2.45
- Cashfrom Financing Activities
- 2.38
- Net Changein Cash
- 0.18
- Period
- 2018
- Total Revenue
- 5.34
- Selling/ General/ Admin Expenses Total
- 1.28
- Depreciation/ Amortization
- 0.74
- Other Operating Expenses Total
- 1.5
- Total Operating Expense
- 4.47
- Operating Income
- 0.87
- Net Income Before Taxes
- 0.95
- Net Income
- 0.53
- Diluted Normalized EPS
- 3.37
- Period
- 2018
- Total Assets
- 24.1
- Total Liabilities
- 9.09
- Total Equity
- 15.01
- Tangible Book Valueper Share Common Eq
- 95.85
- Period
- 2018
- Cashfrom Operating Activities
- 0.84
- Cashfrom Investing Activities
- -4.75
- Cashfrom Financing Activities
- 3.45
- Net Changein Cash
- -0.46
- Period
- 2022-09-30
- Total Revenue
- 3.72
- Selling/ General/ Admin Expenses Total
- 1.17
- Depreciation/ Amortization
- 0.45
- Other Operating Expenses Total
- 0.58
- Total Operating Expense
- 3.7
- Operating Income
- 0.02
- Net Income Before Taxes
- 0.01
- Net Income
- 0.08
- Diluted Normalized EPS
- 0.49
- Period
- 2022-09-30
- Total Assets
- 31.43
- Total Liabilities
- 14.67
- Total Equity
- 16.75
- Tangible Book Valueper Share Common Eq
- 107.01
- Period
- 2022-09-30
- Cashfrom Operating Activities
- 4.5
- Cashfrom Investing Activities
- -1.58
- Cashfrom Financing Activities
- -1.89
- Net Changein Cash
- 1.03
- Period
- 2022-06-30
- Total Revenue
- 6.57
- Selling/ General/ Admin Expenses Total
- 1.34
- Depreciation/ Amortization
- 0.42
- Other Operating Expenses Total
- 0.26
- Total Operating Expense
- 6.03
- Operating Income
- 0.53
- Net Income Before Taxes
- 0.43
- Net Income
- 0.33
- Diluted Normalized EPS
- 2.09
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 11.65
- Selling/ General/ Admin Expenses Total
- 1.58
- Depreciation/ Amortization
- 0.56
- Other Operating Expenses Total
- -0.86
- Total Operating Expense
- 7.96
- Operating Income
- 3.69
- Net Income Before Taxes
- 0.8
- Net Income
- 0.65
- Diluted Normalized EPS
- 4.06
- Period
- 2022-03-31
- Total Assets
- 35.11
- Total Liabilities
- 18.76
- Total Equity
- 16.35
- Tangible Book Valueper Share Common Eq
- 104.43
- Period
- 2022-03-31
- Cashfrom Operating Activities
- 7.78
- Cashfrom Investing Activities
- -1.53
- Cashfrom Financing Activities
- -6.68
- Net Changein Cash
- -0.42
- Period
- 2021-12-31
- Total Revenue
- 2.89
- Selling/ General/ Admin Expenses Total
- 1.15
- Depreciation/ Amortization
- 0.37
- Other Operating Expenses Total
- 1.12
- Total Operating Expense
- 2.89
- Operating Income
- 0
- Net Income Before Taxes
- 0.09
- Net Income
- 0.05
- Diluted Normalized EPS
- 0.31
- Period
- 2021-12-31
- Period
- 2021-12-31
- Period
- 2021-09-30
- Total Revenue
- 2.98
- Selling/ General/ Admin Expenses Total
- 1.13
- Depreciation/ Amortization
- 0.37
- Other Operating Expenses Total
- 1.14
- Total Operating Expense
- 5.29
- Operating Income
- -2.31
- Net Income Before Taxes
- 0.07
- Net Income
- 0.02
- Diluted Normalized EPS
- 0.12
- Period
- 2021-09-30
- Total Assets
- 35.4
- Total Liabilities
- 19.77
- Total Equity
- 15.63
- Tangible Book Valueper Share Common Eq
- 99.84
- Period
- 2021-09-30
- Cashfrom Operating Activities
- -0.12
- Cashfrom Investing Activities
- -0.92
- Cashfrom Financing Activities
- 0.66
- Net Changein Cash
- -0.38
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Technical
Moving Average
SMA
- 5 Day47.34
- 10 Day42.22
- 20 Day35.2
- 50 Day32.46
- 100 Day36.62
- 300 Day30.99
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Novartis India
- 631.45
- -5.75
- -0.9
- 821.8
- 566
- 1584.41
- Fermenbio
- 165.3
- -4.5
- -2.65
- 320
- 166.15
- 489.83
- Titan Biotech
- 278
- -6.6
- -2.32
- 339.7
- 205.4
- 235.18
- Vikram Thermo India
- 65.15
- 1
- 1.56
- 74
- 30.6
- 201.16
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Novartis India
- 55.33
- 2.29
- 4.38
- 7.18
- Fermenbio
- 31.85
- 1.32
- 19.22
- 15.12
- Titan Biotech
- 9.21
- 2.38
- 30.62
- 15.03
- Vikram Thermo India
- 23.5
- 2.74
- 13.52
- 10.53
Shareholding
- Category
- Percentage
- No. of shares
- Public Shareholding
- 50.83%
- 795,905
- YOGESH BIHARILAL PARIKH
- 15.97%
- 250,000
- RAJESHKUMAR VITHALBHAI PATEL
- 2.51%
- 39,285
- RENUKA YOGESH PARIKH
- 15.97%
- 250,000
- Others
- 0.13%
- 2,091
- Others
- 14.58%
- 228,249
- Others
- 0.8%
- 12,500
- Employees
- 0.56%
- 8,768
- HUF
- 0.08%
- 1,273
- Clearing Members
- 0.01%
- 125
- Others
- 0.23%
- 3,614
- Promoter & Promoter Group Shareholding
- 49.17%
- 769,770
- ANAR PROJECT LIMITED
- 18.39%
- 288,000
- PARSHVA TEXCHEM INDIA PRIVATE LTD.
- 16.78%
- 262,770
- NAVKAR SURGICAL GUJARAT
- 11.5%
- 180,000
- DAKSHESH RAMESHCHANDRA SHAH
- 0.77%
- 12,000
- ANAR JAYESHBHAI PATEL
- 0.77%
- 12,000
- SUJAY JYOTINDRA MEHTA
- 0.57%
- 9,000
- PAYAL SUJAY MEHTA
- 0.38%
- 6,000
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 18-Jan-23
- Others
- 12-Nov-22
- Quarterly Results
- 25-Aug-22
- Right issue of Equity Shares
- 06-Aug-22
- Quarterly Results
- 28-May-22
- Audited Results & Others
- 12-Feb-22
- Quarterly Results
- 30-Oct-21
- Quarterly Results
- 14-Aug-21
- Quarterly Results
- 29-Jun-21
- Quarterly Results & Others
- 12-Feb-21
- Quarterly Results
No recent AGMs.
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 30-May-22
- -
- 22-Sept-22
- 0.5
No recent bonus announcements.
No recent splits available.
- Announced on
- Record Date
- Ex-Rights Date
- Ratio
- FV
- Premium
- Description
- 25-Aug-22
- 02-Feb-23
- 02-Feb-23
- 6:1
- 10
- 10
- Rights issue of equity shares of Rs. 10/- in the ratio of 6:1 @ premium of Rs. 10/-.
Company Profile
ABOUT Shukra Pharmaceuticals
- Industry Biotechnology & Drugs
- ISIN INE551C01028
- BSE Code 524632
Shukra Pharmaceuticals Limited is engaged primarily in the business of manufacturing and marketing pharmaceutical products. The Company’s product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti-Bacterial, Anti-Fungal, Anti-Malarial, Anti-Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquillizer, Anti-Depressant, Anti Manic, Anti Emetic, Anti-Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergic, Corticosteroids, Hyper and Hypoglycemic. The Company’s manufacturing plant is situated in the district of Gandhinagar, Rakanpur, and sells both in India and across the globe.
Company Summary
SHUKRA PHARMACEUTICALS SUMMARY
Shukra Pharmaceuticals is trading 4.83% upper at Rs 57.30 as compared to its last closing price. Shukra Pharmaceuticals has been trading in the price range of 57.3 & 57.3. Shukra Pharmaceuticals has given 98.71% in this year & 27.57% in the last 5 days.
Shukra Pharmaceuticals has TTM P/E ratio 28.8 as compared to the sector P/E of 28.39.
The company posted a net profit of 0.08 Crores in its last quarter.
Listed peers of Shukra Pharmaceuticals include Novartis India (-0.9%), Fermenbio (-2.65%), Titan Biotech (-2.32%) etc.
Shukra Pharmaceuticals has a 49.17% promoter holding & 50.83% public holding.
FAQs about Shukra Pharmaceuticals
Shukra Pharmaceuticals is trading at 57.30 as on 2 Feb, 2023 9:36:01 AM. This is 4.83% upper as compared to its previous closing price of 54.66
The market capitalization of Shukra Pharmaceuticals is 41.11 Cr as on 2 Feb, 2023 9:36:01 AM.
The 52 wk high for Shukra Pharmaceuticals is 54.66 whereas the 52 wk low is 11.14
Shukra Pharmaceuticals can be analyzed on the following key metrics -
- TTM P/E: 28.8
- Sector P/E: 28.39
- Dividend Yield: 0%
- D/E ratio: -
Shukra Pharmaceuticals reported a net profit of 0.75 Cr in 2022.
